Skip to main content
. 2021 Mar 21;13(6):1432. doi: 10.3390/cancers13061432

Figure 5.

Figure 5

In vivo pharmacokinetic and toxicity profile of momordicine-I. (A) Concentration-time profile of momordicine-I in C57Bl/6 male mice at 20 mg/kg single dose administered by IP injection or oral gavage (PO). Data is from n = 3 mice and represents mean ± standard deviation. (B) Comparison of metabolic panel from serum among M-I (30 mg/kg/mouse) and BME treated groups with untreated control mice. Small bar indicates standard error.